// App-Quantinova.ai

10019 : Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.

Researchers

Presenter

  • Veerisa Vimolchalao

Principal Investigators

  • Siwat Sakdejayont

  • Ploytuangporn Wongchanapai

  • Shama Sukprakun

  • Suleepon Uttamapinan

  • Nattaya Sintawichai

  • Nattaya Poovorawan

  • Sutima Luangdilok

  • Napa Parinyanitikul

  • Chanida Vinayanuwattikun

  • Virote Sriuranpong

  • Suebpong Tanasanvimon

Medical Centers

  • Division of Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  • Division of Oncology, Chulalongkorn University, Bangkok, Thailand

  • Oncology Section, Production Division, Pharmacy Department, Chulalongkorn University, Bangkok, Thailand

  • Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand

  • Chulalongkorn University/ King Chulalongkorn Memorial Hospital, Bangkok, Thailand

  • Chulabhorn Hospital, Bangkok, Thailand

  • Chulalongkorn University/ King Chulalongkorn Memorial Hospital, Bangkok, Thailand

  • King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Locations

  • Thailand

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Ondansetron

  • Olanzapine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved